Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
about
A rare and distinct tumor of breast cancer: carcinosarcoma, about eight cases and review of the literatureA mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer modelPathways to tamoxifen resistance.Estrogen receptor expression in sporadic vestibular schwannomas.Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cellsThe epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment.Epithelial cell guidance by self-generated EGF gradients.Carcinosarcoma of the breast: two case reports and review of the literature.Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.Smoking out reproductive hormone actions in lung cancer.Estrongenic steroid hormones in lung cancer.Cross-talk and modulation of signaling between somatostatin and growth factor receptors.A rare case of true carcinosarcoma of the breast.Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.The Concept of Divergent Targeting through the Activation and Inhibition of Receptors as a Novel Chemotherapeutic Strategy: Signaling Responses to Strong DNA-Reactive Combinatorial Mimicries.Gefitinib--a novel targeted approach to treating cancer.Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.The Dawning of Translational Breast Cancer: From Bench to Bedside.
P2860
Q26860931-4C5EA739-58B0-4DD9-A395-8BD46DC6325FQ30417300-A8ABA3BE-B135-453A-919D-C5F0EF809AE6Q30441001-284CA8C2-358E-43A0-B529-6BD1B2DDCE9AQ30471838-263A7A0B-0A21-4731-8A79-F4ED351846E7Q33538332-831B70E3-4569-49CB-94F0-9D05625C0885Q34681112-CA8C3201-1191-48BE-BE2E-717E19DC0E89Q35588724-31E7E40F-BB7F-4B25-B688-2CC73B009519Q35648936-69D40095-766C-421D-8A81-9016971E3A43Q36230414-8F05809B-AE95-4270-8DEC-41C806D943D5Q37064671-D53F2B33-087E-4FB9-9560-1D6049768382Q37360151-A4C45B71-EE94-4CB7-A6B6-89BF81BF76B0Q37679479-5B07315C-EFA4-4FB5-8DD8-A517D4BF40DBQ37726987-5A41B26A-23E6-4C65-9B97-EE409B2384CBQ37922648-7305E736-8E3F-4A5D-A9B5-F35B667EC853Q39308385-FCAFDCF3-EE7E-4D5D-9240-81187BF543EFQ39558353-EEF4B45C-BB6D-4D93-9962-D8BE60C7D32EQ41091349-0A04AC1B-A8D4-4F20-B29F-1E1CC63017E3Q42560434-7BE6EF40-1C9A-40D5-95CA-2934FDC7FBE9Q45169148-BDA3D342-254B-40C5-99EA-65CD7B4D8680Q47134459-CD825756-81B5-478F-A876-34C0F6AC2401Q49544424-756C754A-0DDB-4D99-AEB1-DD33B3E2CB37
P2860
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Additive antitumour effect of ...... 82,780) in breast cancer cells
@ast
Additive antitumour effect of ...... 82,780) in breast cancer cells
@en
type
label
Additive antitumour effect of ...... 82,780) in breast cancer cells
@ast
Additive antitumour effect of ...... 82,780) in breast cancer cells
@en
prefLabel
Additive antitumour effect of ...... 82,780) in breast cancer cells
@ast
Additive antitumour effect of ...... 82,780) in breast cancer cells
@en
P2093
P2860
P356
P1476
Additive antitumour effect of ...... 82,780) in breast cancer cells
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601504
P407
P577
2004-01-01T00:00:00Z